Clinical Trials Logo

Refractory Endometrial Carcinoma clinical trials

View clinical trials related to Refractory Endometrial Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT05039801 Recruiting - Clinical trials for Advanced Malignant Solid Neoplasm

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Start date: September 9, 2021
Phase: Phase 1
Study type: Interventional

To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have solid tumors. The safety and tolerability of the study drug(s) will also be studied.

NCT ID: NCT04719273 Active, not recruiting - Clinical trials for Refractory Endometrial Carcinoma

Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer

Start date: January 28, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effect of onapristone and anastrozole in treating patients with hormone receptor positive endometrial cancer that has not responded to previous treatment (refractory). Progesterone and estrogen are hormones that can cause the growth of endometrial cancer cells. Onapristone blocks the use of progesterone by the tumor cells. Anastrozole is a drug that blocks the production of estrogen in the body. Giving onapristone with anastrozole may work better than anastrozole alone in treating patients with hormone receptor positive endometrial cancer.

NCT ID: NCT03008408 Active, not recruiting - Clinical trials for Recurrent Endometrial Carcinoma

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

Start date: August 18, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well everolimus and letrozole with or without ribociclib work in treating participants with endometrial cancer that has spread to other areas of the body or has come back. Ribociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs such as everolimus and letrozole have been shown to be effective at stopping tumor growth either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ribociclib, everolimus, and letrozole may work better than everolimus and letrozole in treating participants with endometrial cancer.